Foreign-Trade Zone (FTZ) 7-Mayaguez, Puerto Rico; Notification of Proposed Production Activity; Bristol-Myers Squibb Holdings Pharma, Ltd.; (Pharmaceuticals); Manati, Puerto Rico, 13578 [2017-04972]

Download as PDF 13578 Federal Register / Vol. 82, No. 48 / Tuesday, March 14, 2017 / Notices Dated: March 8, 2017. David Mussatt, Supervisory Chief, Regional Programs Unit. DEPARTMENT OF COMMERCE [FR Doc. 2017–04912 Filed 3–13–17; 8:45 am] [B–16–2017] Foreign-Trade Zones Board BILLING CODE P Foreign-Trade Zone (FTZ) 7— Mayaguez, Puerto Rico; Notification of Proposed Production Activity; BristolMyers Squibb Holdings Pharma, Ltd.; (Pharmaceuticals); Manati, Puerto Rico DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [Order No. 2030] asabaliauskas on DSK3SPTVN1PROD with NOTICES Reorganization of Foreign-Trade Zone 283 (Expansion of Service Area) Under Alternative Site Framework; West Tennessee Area Pursuant to its authority under the Foreign-Trade Zones Act of June 18, 1934, as amended (19 U.S.C. 81a–81u), the Foreign-Trade Zones Board (the Board) adopts the following Order: Whereas, the Board adopted the alternative site framework (ASF) (15 CFR Sec. 400.2(c)) as an option for the establishment or reorganization of zones; Whereas, the Northwest Tennessee Regional Port Authority, grantee of Foreign-Trade Zone 283, submitted an application to the Board (FTZ Docket B– 53–2016, docketed August 11, 2016) for authority to expand the service area of the zone to include the Counties of Fayette, Hardeman and McNairy as described in the application, adjacent to the Memphis Customs and Border Protection port of entry; Whereas, notice inviting public comment was given in the Federal Register (81 FR 54555, August 16, 2016) and the application has been processed pursuant to the FTZ Act and the Board’s regulations; and, Whereas, the Board adopts the findings and recommendations of the examiner’s report, and finds that the requirements of the FTZ Act and the Board’s regulations are satisfied; Now, therefore, the Board hereby orders: The application to reorganize FTZ 283 to expand the service area under the ASF is approved, subject to the FTZ Act and the Board’s regulations, including Section 400.13, and to the Board’s standard 2,000-acre activation limit for the zone. Dated: March 1, 2017. Ronald K. Lorentzen, Acting Assistant Secretary of Commerce for Enforcement and Compliance, Alternate Chairman, Foreign-Trade Zones Board. [FR Doc. 2017–04911 Filed 3–13–17; 8:45 am] BILLING CODE 3510–DS–P VerDate Sep<11>2014 17:42 Mar 13, 2017 Jkt 241001 Bristol-Myers Squibb Holdings Pharma, Ltd. (BMS) submitted a notification of proposed production activity to the FTZ Board for its facility in Manati, Puerto Rico within Subzone 7J. The notification conforming to the requirements of the regulations of the FTZ Board (15 CFR 400.22) was received on March 6, 2017. BMS already has authority to produce certain pharmaceutical products within Subzone 7J. The current request would add finished products and foreign status materials/components to the scope of authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would be limited to the specific foreign-status materials/components and specific finished products described in the submitted notification (as described below) and subsequently authorized by the FTZ Board. Production under FTZ procedures could exempt BMS from customs duty payments on the foreign-status materials/components used in export production. On its domestic sales, BMS would be able to choose the duty rates during customs entry procedures that apply to: Antisera; blood fractions; peptides and proteins; Orencia® (and other abatacept-containing products); Opdivo® (and other nivolumabcontaining products); Yervoy® (and other ipilimumab-containing products); EmplicitiTM (and other elotuzumabcontaining products); Nulojix® (and other belatacept-containing products); antineoplastic medicaments; and, immunosuppressive medicaments (duty-free) for the foreign-status materials/components noted below and in the existing scope of authority. Customs duties also could possibly be deferred or reduced on foreign-status production equipment. The materials/components sourced from abroad include: Antisera; blood fractions; peptides and proteins; abatacept; belatacept; elotuzumab; ipilimumab; nivolumab; ferments; whole human blood; antiallergenic preparations; antineoplastic medicaments; and, immunosuppressive medicaments (duty-free). Public comment is invited from interested parties. Submissions shall be addressed to the Board’s Executive PO 00000 Frm 00003 Fmt 4703 Sfmt 4703 Secretary at the address below. The closing period for their receipt is April 24, 2017. A copy of the notification will be available for public inspection at the Office of the Executive Secretary, Foreign-Trade Zones Board, Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., Washington, DC 20230–0002, and in the ‘‘Reading Room’’ section of the Board’s Web site, which is accessible via www.trade.gov/ftz. For further information, contact Christopher Wedderburn at Chris.Wedderburn@trade.gov or (202) 482–1963. Dated: March 8, 2017. Andrew McGilvray, Executive Secretary. [FR Doc. 2017–04972 Filed 3–13–17; 8:45 am] BILLING CODE 3510–DS–P DEPARTMENT OF COMMERCE Foreign-Trade Zones Board [S–35–2017] Foreign-Trade Zone 43—Battle Creek, Michigan, Application for Subzone Expansion, Mead Johnson & Company, LLC, Zeeland, Michigan An application has been submitted to the Foreign-Trade Zones (FTZ) Board by the City of Battle Creek, grantee of FTZ 43, requesting an expansion of Subzone 43B on behalf of Mead Johnson & Company, LLC dba Mead Johnson Nutrition (Mead Johnson), located in Zeeland, Michigan. The application was submitted pursuant to the provisions of the Foreign-Trade Zones Act, as amended (19 U.S.C. 81a–81u), and the regulations of the FTZ Board (15 CFR 400). It was formally docketed on March 9, 2017. Subzone 43B currently consists of the following sites: Site 1 (29.63 acres), 725 East Main Street, Zeeland; and, Site 4 (2.3 acres), 8250 Logistics Drive, Zeeland. The applicant is now requesting authority to remove Site 4 and to add a new site: Proposed Site 5 (22.8 acres), 750 East Riley Street, Zeeland. No additional production authority is being requested at this time. The expanded subzone would be subject to the existing activation limit of FTZ 43. In accordance with the FTZ Board’s regulations, Elizabeth Whiteman of the FTZ Staff is designated examiner to review the application and make recommendations to the Executive Secretary. Public comment is invited from interested parties. Submissions shall be E:\FR\FM\14MRN1.SGM 14MRN1

Agencies

[Federal Register Volume 82, Number 48 (Tuesday, March 14, 2017)]
[Notices]
[Page 13578]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04972]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

Foreign-Trade Zones Board

[B-16-2017]


Foreign-Trade Zone (FTZ) 7--Mayaguez, Puerto Rico; Notification 
of Proposed Production Activity; Bristol-Myers Squibb Holdings Pharma, 
Ltd.; (Pharmaceuticals); Manati, Puerto Rico

    Bristol-Myers Squibb Holdings Pharma, Ltd. (BMS) submitted a 
notification of proposed production activity to the FTZ Board for its 
facility in Manati, Puerto Rico within Subzone 7J. The notification 
conforming to the requirements of the regulations of the FTZ Board (15 
CFR 400.22) was received on March 6, 2017.
    BMS already has authority to produce certain pharmaceutical 
products within Subzone 7J. The current request would add finished 
products and foreign status materials/components to the scope of 
authority. Pursuant to 15 CFR 400.14(b), additional FTZ authority would 
be limited to the specific foreign-status materials/components and 
specific finished products described in the submitted notification (as 
described below) and subsequently authorized by the FTZ Board.
    Production under FTZ procedures could exempt BMS from customs duty 
payments on the foreign-status materials/components used in export 
production. On its domestic sales, BMS would be able to choose the duty 
rates during customs entry procedures that apply to: Antisera; blood 
fractions; peptides and proteins; Orencia[supreg] (and other abatacept-
containing products); Opdivo[supreg] (and other nivolumab-containing 
products); Yervoy[supreg] (and other ipilimumab-containing products); 
EmplicitiTM (and other elotuzumab-containing products); 
Nulojix[supreg] (and other belatacept-containing products); 
antineoplastic medicaments; and, immunosuppressive medicaments (duty-
free) for the foreign-status materials/components noted below and in 
the existing scope of authority. Customs duties also could possibly be 
deferred or reduced on foreign-status production equipment.
    The materials/components sourced from abroad include: Antisera; 
blood fractions; peptides and proteins; abatacept; belatacept; 
elotuzumab; ipilimumab; nivolumab; ferments; whole human blood; 
antiallergenic preparations; antineoplastic medicaments; and, 
immunosuppressive medicaments (duty-free).
    Public comment is invited from interested parties. Submissions 
shall be addressed to the Board's Executive Secretary at the address 
below. The closing period for their receipt is April 24, 2017.
    A copy of the notification will be available for public inspection 
at the Office of the Executive Secretary, Foreign-Trade Zones Board, 
Room 21013, U.S. Department of Commerce, 1401 Constitution Avenue NW., 
Washington, DC 20230-0002, and in the ``Reading Room'' section of the 
Board's Web site, which is accessible via www.trade.gov/ftz.
    For further information, contact Christopher Wedderburn at 
Chris.Wedderburn@trade.gov or (202) 482-1963.

    Dated: March 8, 2017.
Andrew McGilvray,
Executive Secretary.
[FR Doc. 2017-04972 Filed 3-13-17; 8:45 am]
 BILLING CODE 3510-DS-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.